Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Doxorubicin-induced skeletal muscle atrophy: elucidating the underlying molecular pathways.

Hiensch AE, Bolam KA, Mijwel S, Jeneson JAL, Huitema ADR, Kranenburg O, van der Wall E, Rundqvist H, Wengstrom Y, May AM.

Acta Physiol (Oxf). 2019 Oct 10:e13400. doi: 10.1111/apha.13400. [Epub ahead of print] Review.

PMID:
31600860
2.

Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study.

den Uil SH, van den Broek E, Coupé VMH, Vellinga TT, Delis-van Diemen PM, Bril H, Belt EJT, Kranenburg O, Stockmann HBAC, Belien JAM, Meijer GA, Fijneman RJA.

BMC Gastroenterol. 2019 Aug 16;19(1):146. doi: 10.1186/s12876-019-1063-4.

3.

Tumor Seeding During Colonoscopy as a Possible Cause for Metachronous Colorectal Cancer.

Backes Y, Seerden TCJ, van Gestel RSFE, Kranenburg O, Ubink I, Schiffelers RM, van Straten D, van der Capellen MS, van de Weerd S, de Leng WWJ, Siersema PD, Offerhaus GJA, Morsink FH, Ramphal W, Sive Droste JT, van Lent AUG, Geesing JMJ, Vleggaar FP, Elias SG, Lacle MM, Moons LMG.

Gastroenterology. 2019 Aug 13. pii: S0016-5085(19)41229-8. doi: 10.1053/j.gastro.2019.07.062. [Epub ahead of print]

PMID:
31419435
4.

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Rovers KP, Lurvink RJ, Wassenaar EC, Kootstra TJ, Scholten HJ, Tajzai R, Deenen MJ, Nederend J, Lahaye MJ, Huysentruyt CJ, van 't Erve I, Fijneman RJ, Constantinides A, Kranenburg O, Los M, Thijs AM, Creemers GM, Burger JW, Wiezer MJ, Boerma D, Nienhuijs SW, de Hingh IH.

BMJ Open. 2019 Jul 27;9(7):e030408. doi: 10.1136/bmjopen-2019-030408.

5.

Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.

Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, Wassenaar ECE, de Hingh IHJT, Rovers KP, van Grevenstein WMU, Laclé MM, Kops GJPL, Borel Rinkes IHM, Kranenburg O.

Br J Surg. 2019 Sep;106(10):1404-1414. doi: 10.1002/bjs.11206. Epub 2019 Jun 14.

6.

Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy.

Driehuis E, Kolders S, Spelier S, Lõhmussaar K, Willems SM, Devriese LA, de Bree R, de Ruiter EJ, Korving J, Begthel H, van Es JH, Geurts V, He GW, van Jaarsveld RH, Oka R, Muraro MJ, Vivié J, Zandvliet MMJM, Hendrickx APA, Iakobachvili N, Sridevi P, Kranenburg O, van Boxtel R, Kops GJPL, Tuveson DA, Peters PJ, van Oudenaarden A, Clevers H.

Cancer Discov. 2019 Jul;9(7):852-871. doi: 10.1158/2159-8290.CD-18-1522. Epub 2019 May 3.

PMID:
31053628
7.

Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids.

Bolhaqueiro ACF, Ponsioen B, Bakker B, Klaasen SJ, Kucukkose E, van Jaarsveld RH, Vivié J, Verlaan-Klink I, Hami N, Spierings DCJ, Sasaki N, Dutta D, Boj SF, Vries RGJ, Lansdorp PM, van de Wetering M, van Oudenaarden A, Clevers H, Kranenburg O, Foijer F, Snippert HJG, Kops GJPL.

Nat Genet. 2019 May;51(5):824-834. doi: 10.1038/s41588-019-0399-6. Epub 2019 Apr 29.

PMID:
31036964
8.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).

BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.

9.

Mouse and human urothelial cancer organoids: A tool for bladder cancer research.

Mullenders J, de Jongh E, Brousali A, Roosen M, Blom JPA, Begthel H, Korving J, Jonges T, Kranenburg O, Meijer R, Clevers HC.

Proc Natl Acad Sci U S A. 2019 Feb 20. pii: 201803595. doi: 10.1073/pnas.1803595116. [Epub ahead of print]

10.

Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures.

van der Waals LM, Laoukili J, Jongen JMJ, Raats DA, Borel Rinkes IHM, Kranenburg O.

Sci Rep. 2019 Jan 28;9(1):819. doi: 10.1038/s41598-018-37316-w.

11.

ALDH1A1 expression is associated with poor differentiation, 'right-sidedness' and poor survival in human colorectal cancer.

van der Waals LM, Borel Rinkes IHM, Kranenburg O.

PLoS One. 2018 Oct 11;13(10):e0205536. doi: 10.1371/journal.pone.0205536. eCollection 2018.

12.

Increased Levels of Oxidative Damage in Liver Metastases Compared with Corresponding Primary Colorectal Tumors: Association with Molecular Subtype and Prior Treatment.

van der Waals LM, Jongen JMJ, Elias SG, Veremiyenko K, Trumpi K, Trinh A, Laoukili J, Ubink I, Schenning-van Schelven SJ, van Diest PJ, Borel Rinkes IHM, Kranenburg O.

Am J Pathol. 2018 Oct;188(10):2369-2377. doi: 10.1016/j.ajpath.2018.06.008. Epub 2018 Jul 20.

PMID:
30031728
13.

Macrophages induce "budding" in aggressive human colon cancer subtypes by protease-mediated disruption of tight junctions.

Trumpi K, Frenkel N, Peters T, Korthagen NM, Jongen JMJ, Raats D, van Grevenstein H, Backes Y, Moons LM, Lacle MM, Koster J, Zwijnenburg D, Borel Rinkes IHM, Kranenburg O.

Oncotarget. 2018 Apr 13;9(28):19490-19507. doi: 10.18632/oncotarget.24626. eCollection 2018 Apr 13.

14.

Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.

Ubink I, van Eden WJ, Snaebjornsson P, Kok NFM, van Kuik J, van Grevenstein WMU, Laclé MM, Sanders J, Fijneman RJA, Elias SG, Borel Rinkes IHM, Aalbers AGJ, Kranenburg O.

Br J Surg. 2018 Jan;105(2):e204-e211. doi: 10.1002/bjs.10788.

PMID:
29341165
15.

Anatomic versus Metabolic Tumor Response Assessment after Radioembolization Treatment.

Jongen JMJ, Rosenbaum CENM, Braat MNGJA, van den Bosch MAAJ, Sze DY, Kranenburg O, Borel Rinkes IHM, Lam MGEH, van den Hoven AF.

J Vasc Interv Radiol. 2018 Feb;29(2):244-253.e2. doi: 10.1016/j.jvir.2017.09.024. Epub 2017 Dec 14.

PMID:
29249594
16.

Downregulation of DNA repair proteins and increased DNA damage in hypoxic colon cancer cells is a therapeutically exploitable vulnerability.

Jongen JMJ, van der Waals LM, Trumpi K, Laoukili J, Peters NA, Schenning-van Schelven SJ, Govaert KM, Borel Rinkes IHM, Kranenburg O.

Oncotarget. 2017 Sep 21;8(49):86296-86311. doi: 10.18632/oncotarget.21145. eCollection 2017 Oct 17.

17.

Surgery-induced tumor growth in (metastatic) colorectal cancer.

Govaert KM, Jongen JMJ, Kranenburg O, Borel Rinkes IHM.

Surg Oncol. 2017 Dec;26(4):535-543. doi: 10.1016/j.suronc.2017.10.004. Epub 2017 Oct 17. Review.

PMID:
29113675
18.

Lymphangiogenic Gene Expression Is Associated With Lymph Node Recurrence and Poor Prognosis After Partial Hepatectomy for Colorectal Liver Metastasis.

Vellinga TT, Kranenburg O, Frenkel N, Ubink I, Marvin D, Govaert K, van Schelven S, Hagendoorn J, Borel Rinkes IH.

Ann Surg. 2017 Nov;266(5):765-771. doi: 10.1097/SLA.0000000000002430.

PMID:
28742689
19.

Neoadjuvant chemotherapy affects molecular classification of colorectal tumors.

Trumpi K, Ubink I, Trinh A, Djafarihamedani M, Jongen JM, Govaert KM, Elias SG, van Hooff SR, Medema JP, Lacle MM, Vermeulen L, Borel Rinkes IHM, Kranenburg O.

Oncogenesis. 2017 Jul 10;6(7):e357. doi: 10.1038/oncsis.2017.48.

20.

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).

Ubink I, Bloemendal HJ, Elias SG, Brink MA, Schwartz MP, Holierhoek YCW, Verheijen PM, Boerman AW, Mathijssen RHJ, de Leng WWJ, de Weger RA, van Grevenstein WMU, Koopman M, Lolkema MP, Kranenburg O, Borel Rinkes IHM.

BMC Cancer. 2017 Apr 19;17(1):282. doi: 10.1186/s12885-017-3264-y.

21.

A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.

Ubink I, Elias SG, Moelans CB, Laclé MM, van Grevenstein WMU, van Diest PJ, Borel Rinkes IHM, Kranenburg O.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw303.

PMID:
28376187
22.

CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage.

Raats DA, Frenkel N, van Schelven SJ, Rinkes IH, Laoukili J, Kranenburg O.

Cell Death Dis. 2017 Mar 16;8(3):e2669. doi: 10.1038/cddis.2017.87.

23.

Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer.

Borovski T, Vellinga TT, Laoukili J, Santo EE, Fatrai S, van Schelven S, Verheem A, Marvin DL, Ubink I, Borel Rinkes IHM, Kranenburg O.

Gut. 2017 Jun;66(6):1106-1115. doi: 10.1136/gutjnl-2016-311547. Epub 2016 Sep 26.

PMID:
27670374
24.

A potential role for CCN2/CTGF in aggressive colorectal cancer.

Ubink I, Verhaar ER, Kranenburg O, Goldschmeding R.

J Cell Commun Signal. 2016 Sep;10(3):223-227. Epub 2016 Sep 10.

25.

Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.

Trinh A, Trumpi K, De Sousa E Melo F, Wang X, de Jong JH, Fessler E, Kuppen PJ, Reimers MS, Swets M, Koopman M, Nagtegaal ID, Jansen M, Hooijer GK, Offerhaus GJ, Kranenburg O, Punt CJ, Medema JP, Markowetz F, Vermeulen L.

Clin Cancer Res. 2017 Jan 15;23(2):387-398. doi: 10.1158/1078-0432.CCR-16-0680. Epub 2016 Jul 26.

26.

Surgical resection and radiofrequency ablation initiate cancer in cytokeratin-19+- liver cells deficient for p53 and Rb.

Matondo RB, Toussaint MJ, Govaert KM, van Vuuren LD, Nantasanti S, Nijkamp MW, Pandit SK, Tooten PC, Koster MH, Holleman K, Schot A, Gu G, Spee B, Roskams T, Rinkes IB, Schotanus B, Kranenburg O, de Bruin A.

Oncotarget. 2016 Aug 23;7(34):54662-54675. doi: 10.18632/oncotarget.9952.

27.

Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion.

Vellinga TT, den Uil S, Rinkes IH, Marvin D, Ponsioen B, Alvarez-Varela A, Fatrai S, Scheele C, Zwijnenburg DA, Snippert H, Vermeulen L, Medema JP, Stockmann HB, Koster J, Fijneman RJ, de Rooij J, Kranenburg O.

Oncogene. 2016 Oct 6;35(40):5263-5271. doi: 10.1038/onc.2016.60. Epub 2016 Mar 21.

PMID:
26996663
28.

Mice lacking functional CD95-ligand display reduced proliferation of the intestinal epithelium without gross homeostatic alterations.

Trumpi K, Steller EJ, de Leng WW, Raats DA, Nijman IJ, Morsink FH, Borel Rinkes IH, Kranenburg O.

Med Mol Morphol. 2016 Jun;49(2):110-8. doi: 10.1007/s00795-015-0129-9. Epub 2015 Dec 23.

PMID:
26700225
29.

ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer.

Trumpi K, Emmink BL, Prins AM, van Oijen MG, van Diest PJ, Punt CJ, Koopman M, Kranenburg O, Rinkes IH.

J Cancer. 2015 Sep 3;6(11):1079-86. doi: 10.7150/jca.12606. eCollection 2015.

30.

Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.

Heerma van Voss MR, Vesuna F, Trumpi K, Brilliant J, Berlinicke C, de Leng W, Kranenburg O, Offerhaus GJ, Bürger H, van der Wall E, van Diest PJ, Raman V.

Oncotarget. 2015 Sep 29;6(29):28312-26. doi: 10.18632/oncotarget.4873.

31.

Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells.

Fatrai S, van Schelven SJ, Ubink I, Govaert KM, Raats D, Koster J, Verheem A, Borel Rinkes IH, Kranenburg O.

Gastroenterology. 2015 Sep;149(3):692-704. doi: 10.1053/j.gastro.2015.05.003. Epub 2015 May 9.

PMID:
25962936
32.

SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer.

Vellinga TT, Borovski T, de Boer VC, Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink BL, Koster J, Rinkes IH, Kranenburg O.

Clin Cancer Res. 2015 Jun 15;21(12):2870-9. doi: 10.1158/1078-0432.CCR-14-2290. Epub 2015 Mar 16.

33.

Paired image- and FACS-based toxicity assays for high content screening of spheroid-type tumor cell cultures.

Trumpi K, Egan DA, Vellinga TT, Borel Rinkes IH, Kranenburg O.

FEBS Open Bio. 2015 Jan 28;5:85-90. doi: 10.1016/j.fob.2015.01.003. eCollection 2015.

34.

Prometastatic NOTCH Signaling in Colon Cancer.

Kranenburg O.

Cancer Discov. 2015 Feb;5(2):115-7. doi: 10.1158/2159-8290.CD-14-1456.

35.

Wnt signalling induces accumulation of phosphorylated β-catenin in two distinct cytosolic complexes.

Gerlach JP, Emmink BL, Nojima H, Kranenburg O, Maurice MM.

Open Biol. 2014 Nov;4(11):140120. doi: 10.1098/rsob.140120.

36.

GPx2 suppression of H2O2 stress links the formation of differentiated tumor mass to metastatic capacity in colorectal cancer.

Emmink BL, Laoukili J, Kipp AP, Koster J, Govaert KM, Fatrai S, Verheem A, Steller EJ, Brigelius-Flohé R, Jimenez CR, Borel Rinkes IH, Kranenburg O.

Cancer Res. 2014 Nov 15;74(22):6717-30. doi: 10.1158/0008-5472.CAN-14-1645. Epub 2014 Sep 26.

37.

Recurrence location after resection of colorectal liver metastases influences prognosis.

Govaert KM, van Kessel CS, Steller EJ, Emmink BL, Molenaar IQ, Kranenburg O, van Hillegersberg R, Borel Rinkes IH.

J Gastrointest Surg. 2014 May;18(5):952-60. doi: 10.1007/s11605-014-2461-0. Epub 2014 Jan 29.

PMID:
24474631
38.

Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells.

Govaert KM, Emmink BL, Nijkamp MW, Cheung ZJ, Steller EJ, Fatrai S, de Bruijn MT, Kranenburg O, Borel Rinkes IH.

Ann Surg. 2014 Apr;259(4):750-9. doi: 10.1097/SLA.0b013e318295c160.

PMID:
24253142
39.

Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer.

Snoeren N, Emmink BL, Koerkamp MJ, van Hooff SR, Goos JA, van Houdt WJ, de Wit M, Prins AM, Piersma SR, Pham TV, Belt EJ, Bril H, Stockmann HB, Meijer GA, van Hillegersberg R, Holstege FC, Jimenez CR, Fijneman RJ, Kranenburg OW, Rinkes IH.

Br J Cancer. 2013 Sep 17;109(6):1636-47. doi: 10.1038/bjc.2013.489. Epub 2013 Sep 3.

40.

The secretome of colon cancer stem cells contains drug-metabolizing enzymes.

Emmink BL, Verheem A, Van Houdt WJ, Steller EJ, Govaert KM, Pham TV, Piersma SR, Borel Rinkes IH, Jimenez CR, Kranenburg O.

J Proteomics. 2013 Oct 8;91:84-96. doi: 10.1016/j.jprot.2013.06.027. Epub 2013 Jul 5.

PMID:
23835434
41.

PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells.

Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, Snoeren N, van Hooff SR, Holstege FC, Maas C, Borel Rinkes IH, Kranenburg O.

Neoplasia. 2013 Feb;15(2):204-17.

42.

Surgical implantation of an abdominal imaging window for intravital microscopy.

Ritsma L, Steller EJ, Ellenbroek SI, Kranenburg O, Borel Rinkes IH, van Rheenen J.

Nat Protoc. 2013 Mar;8(3):583-94. doi: 10.1038/nprot.2013.026. Epub 2013 Feb 21.

PMID:
23429719
43.

The value of miRNA in diagnosing thyroid cancer: a systematic review.

Lodewijk L, Prins AM, Kist JW, Valk GD, Kranenburg O, Rinkes IH, Vriens MR.

Cancer Biomark. 2012;11(6):229-38. doi: 10.3233/CBM-2012-0273. Review.

PMID:
23248180
44.

Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis.

Ritsma L, Steller EJ, Beerling E, Loomans CJ, Zomer A, Gerlach C, Vrisekoop N, Seinstra D, van Gurp L, Schäfer R, Raats DA, de Graaff A, Schumacher TN, de Koning EJ, Rinkes IH, Kranenburg O, van Rheenen J.

Sci Transl Med. 2012 Oct 31;4(158):158ra145. doi: 10.1126/scitranslmed.3004394.

45.

Proteomics in studying cancer stem cell biology.

Kranenburg O, Emmink BL, Knol J, van Houdt WJ, Rinkes IH, Jimenez CR.

Expert Rev Proteomics. 2012 Jun;9(3):325-36. doi: 10.1586/epr.12.24. Review.

PMID:
22809210
46.

CD95 signaling in colorectal cancer.

Hoogwater FJ, Steller EJ, Westendorp BF, Borel Rinkes IH, Kranenburg O.

Biochim Biophys Acta. 2012 Aug;1826(1):189-98. doi: 10.1016/j.bbcan.2012.03.007. Epub 2012 Mar 31. Review.

PMID:
22498253
47.

Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation.

Govaert KM, Nijkamp MW, Emmink BL, Steller EJ, Minchinton AI, Kranenburg O, Borel Rinkes IH.

Br J Surg. 2012 Apr;99(4):567-75. doi: 10.1002/bjs.8668. Epub 2012 Feb 13.

PMID:
22331808
48.

Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases.

Hoogwater FJ, Snoeren N, Nijkamp MW, Gunning AC, VAN Houdt WJ, DE Bruijn MT, Voest EE, VAN Hillegersberg R, Kranenburg O, Rinkes IH.

Anticancer Res. 2011 Dec;31(12):4507-12.

PMID:
22199323
49.

How CD95 stimulates invasion.

Steller EJ, Borel Rinkes IH, Kranenburg O.

Cell Cycle. 2011 Nov 15;10(22):3857-62. doi: 10.4161/cc.10.22.18290. Epub 2011 Nov 15. Review.

PMID:
22064519
50.

Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target.

Van Houdt WJ, Emmink BL, Pham TV, Piersma SR, Verheem A, Vries RG, Fratantoni SA, Pronk A, Clevers H, Borel Rinkes IH, Jimenez CR, Kranenburg O.

Mol Cell Proteomics. 2011 Dec;10(12):M111.011353. doi: 10.1074/mcp.M111.011353. Epub 2011 Jul 25.

Supplemental Content

Loading ...
Support Center